Abstract
Zafirlukast is a leukotriene inhibitor that has recently been approved for the prophylaxis of asthma. Although this new product has been well accepted because of its convenient dosing and relatively few side effects, several cases of Churg–Strauss syndrome have been reported to be associated with its use. In this paper we describe the case of a 54-year-old white man with no history of corticosteroid therapy in whom leukocytoclastic vasculitis, hepatitis and eosinophilia developed while he was on zafirlukast therapy for mild asthma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 20 March 2001 / Accepted: 29 October 2001
Rights and permissions
About this article
Cite this article
Soy, M., Ozer, H., Canataroglu, A. et al. Vasculitis Induced by Zafirlukast Therapy. Clin Rheumatol 21, 328–329 (2002). https://doi.org/10.1007/s100670200086
Published:
Issue Date:
DOI: https://doi.org/10.1007/s100670200086